AstraZeneca, chasing immunotherapy rivals, claims study success in early lung cancer

A regimen involving AstraZeneca’s immunotherapy Imfinzi met the first of two main study goals in a Phase 3 trial in early non-small cell lung cancer, the British drugmaker said Thursday.